Tumor foci treated with RFA were found to be significantly more responsive to the PD‐L1 monoclonal antibody atelectilizumab than those not treated with RFA in a comparative study of two squamous cancer metastases in a patient with NSCLC.76 This evidence concerns the gene CD274 and neoplasm.